Malignant Peritoneal Mesothelioma: Treatment Options and Survival

Malignant peritoneal mesothelioma (MPeM) is a rare type of cancer with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival. Treatment and survival of patients with MPeM have not been previously studied in Finland. T...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-02, Vol.39 (2), p.839-845
Main Authors: Salo, Silja A S, Ilonen, Ilkka, Laaksonen, Sanna, Myllärniemi, Marjukka, Salo, Jarmo A, Rantanen, Tuomo
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Asbestos
Asbestos - adverse effects
Cancer
Chemotherapy
Cytoreduction Surgical Procedures - mortality
Female
Finland
Humans
Hyperthermia, Induced
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - surgery
Male
Medical prognosis
Mesothelioma
Mesothelioma - drug therapy
Mesothelioma - mortality
Mesothelioma - surgery
Mesothelioma, Malignant
Middle Aged
Patients
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - mortality
Peritoneal Neoplasms - surgery
Peritoneum
Prognosis
Radiation
Retrospective Studies
Surgery
Survival
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant peritoneal mesothelioma (MPeM) is a rare type of cancer with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival. Treatment and survival of patients with MPeM have not been previously studied in Finland. The data consisted of all patients diagnosed with MPeM during years 2000-2012 in Finland, including cancer notifications, death certificates and information about asbestos exposure. Among 50/94 (53.2%) patients treated for MPeM, 44/50 (88.0%) were treated palliatively, 4/50 (8.0%) with radical surgery and chemotherapy, and 2/50 (4.0%) with CRS plus HIPEC. Five-year survival was 50.0% for those treated with CRS plus HIPEC and 75.0% for those treated with radical surgery and chemotherapy. Radical surgery with chemotherapy was associated with significantly longer survival compared to radiation (p=0.008), chemotherapy and radiation (p=0.043), surgery, chemotherapy and radiation (p=0.039), and palliative surgery (p=0.009). Treatment of MPeM is heterogenic in Finland. CRS plus HIPEC, and radical surgery with chemotherapy seem to increase the survival. Patients considered candidates for radical surgery should be sent to specialized centers for further assessment.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13183